Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort

Zhu, Yao; Han, Cheng Tao; Chen, Hai Tao; Liu, Fang; Zhang, Gui Ming; Yang, Wei; Xu, Jian; Ye, Ding Wei

doi:10.18632/oncotarget.3938

“…Importantly, all published studies to date demonstrate that GRS based on PCa-risk SNPs is informative in measuring a man's disease risk and can serve as an independent predictor of PCa. 34 41 42 43 …”

Section: Prostate Cancer Risk Snps and Genetic Risk Scorementioning

confidence: 99%

A comparison of genetic risk score with family history for estimating prostate cancer risk

Helfand¹

2016

View full text Add to dashboard Cite

Prostate cancer (PCa) testing is recommended by most authoritative groups for high-risk men including those with a family history of the disease. However, family history information is often limited by patient knowledge and clinician intake, and thus, many men are incorrectly assigned to different risk groups. Alternate methods to assess PCa risk are required. In this review, we discuss how genetic variants, referred to as PCa-risk single-nucleotide polymorphisms, can be used to calculate a genetic risk score (GRS). GRS assigns a relatively unique value to all men based on the number of PCa-risk SNPs that an individual carries. This GRS value can provide a more precise estimate of a man's PCa risk. This is particularly relevant in situations when an individual is unaware of his family history. In addition, GRS has utility and can provide a more precise estimate of risk even among men with a positive family history. It can even distinguish risk among relatives with the same degree of family relationships. Taken together, this review serves to provide support for the clinical utility of GRS as an independent test to provide supplemental information to family history. As such, GRS can serve as a platform to help guide-shared decision-making processes regarding the timing and frequency of PCa testing and biopsies.

show abstract

“…[ 51 ] These figures suggest that the prevalence of high-risk PCa is lower in the USA, the UK, and Germany than in West Africa and Asia [ Table 2 ]. [ 3 28 29 31 36 37 40 41 52 53 54 55 56 57 58 59 60 61 ] An earlier study shows that the death risk of patients with a GS of 7 to 10 range from 29% to 43%, irrespective of age. [ 62 ] This might be due to a lower prevalence of pathogenic mutation (BRCA1/2) in GS ≤ 6 (0.6%) than in GS ≥ 7 (1.2%–3.4%).…”

Section: Gleason Score Of Prostate Cancer In West Africa and Asiamentioning

confidence: 99%

High mortality risk of prostate cancer patients in Asia and West Africa: A systematic review

Okoye

¹

2020

Avicenna J Med

4

0

View full text Add to dashboard Cite

Globally, prostate cancer (PCa) is the second most preponderant cancer in men. It contributes to the high mortality-to-incidence ratio reported in West Africa and Asia largely due to low screening. The mortality risk is determined or predicted based on the prevalence of high-risk or aggressive PCa using a scoring or grading system such as Gleason score (GS), Gleason grade (GG), and prostate-specific antigen (PSA) level. In this review, peer-reviewed articles found on databases such as Google Scholar, Scopus, Web of Science, PubMed Central and, EMBASE were selected based on adherence to clinical guidelines for the classification of PCa. In West Africa and Asia, the result revealed that the frequency of high-risk PCa was 42% and 51.2% based on GS, 48.8% and 25.3% based on GG pattern, and 87.5% and 44.3% based on PSA level >10 ng/mL, respectively. Data revealed a high prevalence of high-risk PCa both in West Africa and Asia when compared with developed countries. However, the prevalence of high-risk PCa is higher in West Africa than in Asia. Studies have shown that high-risk PCas are associated with germline mutations and such mutations are prevalent in blacks and Asians than in whites. Thus, testing for germline mutations in patients with GS of ≥ 7, GG ≥ 3, high prostate density, low prostate volume, and PSA levels of >4.0 ng/mL may identify those at risk of developing lethal PCa and could reduce the mortality rates in Asia and West Africa.

show abstract

“…It also shows that BPH can be found in individuals younger <40 years of age Asia [Table 2]. [3,28,29,31,36,37,40,41,[52][53][54][55][56][57][58][59][60][61] An earlier study shows that the death risk of patients with a GS of 7 to 10 range from 29% to 43%, irrespective of age. [62] This might be due to a lower prevalence of pathogenic mutation (BRCA1/2) in GS ≤ 6 (0.6%) than in GS ≥ 7 (1.2%-3.4%).…”

Section: Gleason Score Of Prostate Cancer In West Africa and Asiamentioning

confidence: 99%

Untitled

2020

Avicenna J Med

0

View full text Add to dashboard Cite

Globally, prostate cancer (PCa) is the second most preponderant cancer in men. It contributes to the high mortality-to-incidence ratio reported in West Africa and Asia largely due to low screening. The mortality risk is determined or predicted based on the prevalence of high-risk or aggressive PCa using a scoring or grading system such as Gleason score (GS), Gleason grade (GG), and prostate-specific antigen (PSA) level. In this review, peer-reviewed articles found on databases such as Google Scholar, Scopus, Web of Science, PubMed Central and, EMBASE were selected based on adherence to clinical guidelines for the classification of PCa. In West Africa and Asia, the result revealed that the frequency of high-risk PCa was 42% and 51.2% based on GS, 48.8% and 25.3% based on GG pattern, and 87.5% and 44.3% based on PSA level >10 ng/mL, respectively. Data revealed a high prevalence of high-risk PCa both in West Africa and Asia when compared with developed countries. However, the prevalence of high-risk PCa is higher in West Africa than in Asia. Studies have shown that high-risk PCas are associated with germline mutations and such mutations are prevalent in blacks and Asians than in whites. Thus, testing for germline mutations in patients with GS of ≥ 7, GG ≥ 3, high prostate density, low prostate volume, and PSA levels of >4.0 ng/mL may identify those at risk of developing lethal PCa and could reduce the mortality rates in Asia and West Africa.

show abstract

Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort

Cited by 10 publications

References 15 publications

A comparison of genetic risk score with family history for estimating prostate cancer risk

A comparison of genetic risk score with family history for estimating prostate cancer risk

High mortality risk of prostate cancer patients in Asia and West Africa: A systematic review

Untitled

Contact Info

Product

Resources

About